China’s Tasly Pharma has in-licensed China rights to two heart drugs from Mesoblast of Australia in a $90 million agreement. Tasly will develop, manufacture and sell two Mesoblast allogeneic mesenchymal precursor cell (MPC) candidates: MPC-150-IM to treat or prevent chronic heart failure and MPC-25-IC to treat or prevent acute myocardial infarction. Tasly will pay $40 million upfront — a $20 million payment and a $20 million investment in Mesoblast.
Source: China Biotoday
